Senior Lecturer & Consultant Medical Oncologist in Advanced #Immunotherapy + #CellTherapy at @manchester.ac.uk & The Christie • RISE Lead & MANIFEST Deputy Lead • ESMO #TranslationalResearch Faculty
🔗 Bio: bit.ly/Christie_JLim
(tennis enthusiast 🎾)
Jon Lim, FRCP PhD
Loading...
Almost 2️⃣ years in…
Our MANIFEST AGM convened scientists, clinicians, patient partners & industry. Keynotes from Prof Levesque & Prof Rattray + Prof Turajlić setting the course ahead.
Big thank you to all for continuing to believe in the vision; to tackle the hard questions in #CancerImmunotherapy.
🚨 We're looking for an Associate Director for Strategy & Partnerships — a pivotal leadership role that will help define how we connect, collaborate, and amplify our impact on a global stage of cancer research!
Apply below by 26.05.2026! 👇
www.cruk.manchester.ac.uk/career/mi-26...
Salary - ~£80,000
We're thrilled to see our Director, Samra Turajlić be awarded the Kidney Cancer Association Pieter De Mulder award for contributions towards the treatment of kidney cancer 🎉
Samra's research group is investigating how and why kidney cancer evolves to increase the success of treatment strategies 🧪
🚨 Open for applications - Director of Scientific Core Facilities & Services!
Shape the strategic future of our core facilities and work with leading experts on cutting-edge cancer discovery and translational research 🧑🔬🔬🧪
💷 ~£100,000 ⏰ 17.5.2026
Apply 👉 www.cruk.manchester.ac.uk/career/mi-26...
#ESMOTAT26: Drug development in oncology is increasingly moving towards integrated strategies that consider tumour cells, their microenvironment and anatomical context.
Read the Opinion by Jon Lim, FRCP PhD in the #ESMODailyReporter 📌 https://ow.ly/fFUx50YJxOP
Nice celebration @reisesousalab.bsky.social of our recently published or in press papers. L-R: Tom Castro-Dopico, Oliver Schulz, @drjonlim.bsky.social and Mike Buck. See earlier and forthcoming posts for paper details.
Jon Lim, FRCP PhD
Cancer Research UK Manchester Institute
Cancer Research UK Manchester Institute
Cancer Research UK Manchester Institute
🚀 We’re hiring: 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗣𝗿𝗼𝗷𝗲𝗰𝘁 𝗠𝗮𝗻𝗮𝗴𝗲𝗿 𝗶𝗻 𝗜𝗺𝗺𝘂𝗻𝗼-𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆
An exciting 🆕 role which sits at the heart of a highly collaborative & ambitious ecosystem spanning the Manchester Immuno-Oncology Network (MION) + the Advanced Immunotherapy and Cell Therapy (AICT) programme.
📩 Deadline 9th April 2026.
Tumour infiltrating lymphocyte (TIL) therapy is here to stay...but toxicity may be the real bottleneck.
Most of it is not the TILs - it’s everything around them. We unpack this in our latest review.
Available #OpenAccess - 𝘑 𝘐𝘮𝘮𝘶𝘯𝘰𝘛𝘩𝘦𝘳 𝘊𝘢𝘯𝘤𝘦𝘳 @sitcancer.bsky.social👇
🔗 jitc.bmj.com/content/14/4...
Fantastic 2 days in San Diego 🌴
for the inaugural C8 Early Career Investigators Symposium.
Happy to represent #TeamManchester + connect with an inspiring group 🌍.
A reminder that we’re not navigating academia alone - great to hear re: lessons learned & tips for future 🤝.
@mcrcnews.bsky.social
💥 Really pleased to see this story finally out in @natcancer.nature.com. An elegant study built around a very cool concept. Huge congratulations to Tom Castro-Dopico, @reisesousalab.bsky.social and all colleagues involved - delighted to have played a small part in it the journey.
@crick.ac.uk
Delighted that our paper is out @natcancer.nature.com. Research led by Tom Castro-Dopico in partnership with Adendra Therapeutics reporting on a means to increase presentation of antigens from cancer cells. Read it for free at www.nature.com/articles/s43...
Caetano Reis e Sousa
Castro-Dopico et al. report the design of reagents to bridge F-actin and Fcγ receptors, endowing a range of antigen-presenting cells with the ability to cross-present antigens from dead tumor cells an...
Researchers at the Crick have found a way to redirect immune cells using F-actin exposed from dead cancer cells, reducing tumour growth in mice.
The technique opens new avenues for developing immunotherapy treatments that complement existing clinical approaches.
www.crick.ac.uk/news/2026-05...
New research from the Francis Crick Institute and Adendra Therapeutics shows that immune cells can be redirected to recognise cancer by exploiting F‑actin, a structural protein exposed when tumour cel...
